An Unusual Cause of Gastrointestinal Perforation in an Adolescent Patient With Beta-Thalassemia on Deferasirox and SARS-CoV-2 Infection
- PMID: 34007369
- PMCID: PMC8110227
- DOI: 10.14740/jh815
An Unusual Cause of Gastrointestinal Perforation in an Adolescent Patient With Beta-Thalassemia on Deferasirox and SARS-CoV-2 Infection
Abstract
Chelation therapy is recognized as a safe and effective treatment option in patients with beta-thalassemia with iron overload. We report an 18-year-old male with acute abdomen and gastrointestinal bleeding with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection secondary to gastric perforation due to chelation therapy. This patient had a prolonged intensive care stay with complications of SARS-CoV-2 and a small bowel obstruction post-surgery that resolved after conservative management. Given the acute presentation, chelation therapy use and concomitant SARS-CoV-2 infection, clinicians should keep an open mind on the differential diagnosis of acute abdomen in patients with beta-thalassemia.
Keywords: Anti-chelation therapy; Gastric perforation; SARS-CoV-2; Thalassemia.
Copyright 2021, Chauhan et al.
Conflict of interest statement
None to declare.
Figures


Similar articles
-
Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.Infect Disord Drug Targets. 2015;15(2):98-105. doi: 10.2174/1871526515666150724111721. Infect Disord Drug Targets. 2015. PMID: 26205801
-
Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.Hemoglobin. 2015;39(5):327-9. doi: 10.3109/03630269.2015.1057735. Epub 2015 Jun 26. Hemoglobin. 2015. PMID: 26114738
-
Human and novel coronavirus infections in children: a review.Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25. Paediatr Int Child Health. 2021. PMID: 32584199 Review.
-
Thalassemia.Hematology Am Soc Hematol Educ Program. 2004:14-34. doi: 10.1182/asheducation-2004.1.14. Hematology Am Soc Hematol Educ Program. 2004. PMID: 15561674 Review.
-
Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.Blood. 2011 Jul 28;118(4):884-93. doi: 10.1182/blood-2010-11-316646. Epub 2011 May 31. Blood. 2011. PMID: 21628399 Clinical Trial.
Cited by
-
COVID-19 and Malignancy: What is the Association? A Case Report and Review of the Literature.Med Arch. 2023;77(3):237-240. doi: 10.5455/medarh.2023.77.237-240. Med Arch. 2023. PMID: 37700926 Free PMC article. Review.
-
Coronavirus Disease in the Abdomen.Adv Clin Radiol. 2022 Sep;4(1):25-35. doi: 10.1016/j.yacr.2022.04.003. Epub 2022 Sep 14. Adv Clin Radiol. 2022. PMID: 37521427 Free PMC article. Review.
-
Therapeutic potential of induced iron depletion using iron chelators in Covid-19.Saudi J Biol Sci. 2022 Apr;29(4):1947-1956. doi: 10.1016/j.sjbs.2021.11.061. Epub 2021 Dec 13. Saudi J Biol Sci. 2022. PMID: 34924800 Free PMC article. Review.
References
-
- Cappellini MD, Cohen A, Eleftheriou A. et al. Guidelines for the Clinical Management of Thalassaemia [Internet]. 2nd Revised edition. Nicosia (CY): Thalassaemia International Federation; 2008. Chapter 18, Outline of Diagnostic Dilemmas in Thalassaemia. Available from: https://www.ncbi.nlm.nih.gov/books/NBK173977/ - PubMed
-
- Pennell DJ, Porter JB, Piga A, Lai Y, El-Beshlawy A, Belhoul KM, Elalfy M. et al. A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in beta-thalassemia major (CORDELIA) Blood. 2014;123(10):1447–1454. doi: 10.1182/blood-2013-04-497842. - DOI - PMC - PubMed
-
- Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, Kriemler-Krahn U. et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol. 2009;82(6):458–465. doi: 10.1111/j.1600-0609.2009.01228.x. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous